Efficacy of suppository naproxen in prevention of pancreatitis
Phase 2
- Conditions
- acute pancreatitis.other acute pancreatitis
- Registration Number
- IRCT201105301155N14
- Lead Sponsor
- Behvazan Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 324
Inclusion Criteria
All patients over 18 years who were referred to hospital for ERCP; disorders in liver function tests; had extrahepatic cholestasis.
Exclusion criteria: Acute pancreatitis in the last two weeks; history of chronic pancreatitis; a history of previous sphincterotomy; NSAID use in a week; contraindication for NSAID use such as renal failure and having allergy to the drug; peptic ulcer with recent GI bleeding; not consent to participate in this plan.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pancreatitis. Timepoint: 24 hours after ERCP. Method of measurement: Amylase serum, Patient's symptoms(nausea, vomiting and abdominal pain).
- Secondary Outcome Measures
Name Time Method